alexa Abstract | Positioning for Success in University-Industry Drug-Discovery Collaborations: Initiatives towards Effective Trans-Constituency Team Science

International Journal of Drug Development and Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Despite entrenched differences between academia and the industrial sector, business models partnering universities and commercial entities to conduct preclinical drug-discovery team science are increasingly prevalent as attempts to boost and de-risk therapeutics invention. This dichotomy invites consideration of three high-level contextual elements that can help such trans-constituency alliances actualize their potential: an enabling operational profile as strategic roadmap; milestones supporting project progress and inviting improvement; and a critical mass of capable, engaged academic and industrial co-participants working across institutional boundaries and sharing risks and rewards. These elements bring many (in)tangible and often underappreciated benefits to a research-driven public-private discovery collaboration, e.g., underscoring its translational nature; acknowledging the important roles of vigilant self-evaluation and change; setting trust and quality expectations; establishing lines of communication and accountability; inviting knowledge cross-pollination; and avoiding project compromise by cross- purpose activities and personal/institutional self-interests. Although the inherently unpredictable nature of scientific progress and the heterogeneity of university-industry discovery collaborations preclude a universal success formula, pragmatic enablers discussed can help such alliances between academia and pharma/biotech traverse the rugged terrain at the science-business interface.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): David R Janero


Alliance partnerships, Consultants, Discovery collaborations, Economics, Entrepreneurship, Pharmacological invention, Preclinical research, Therapeutics discovery, Universities, Industrial Pharmacy, Drug Research and Discovery Process

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version